TriSalus Life Sciences (TLSIW) Net Cash Flow (2021 - 2026)

TriSalus Life Sciences has reported Net Cash Flow for 6 years, with the latest figure at $35.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 699.2% year-over-year to $35.8 million; the trailing twelve-month figure through Mar 2026 stood at $43.2 million (up 378.44% YoY), and the FY2025 full-year result was $11.9 million, up 466.36% from the prior year.
• Net Cash Flow for Q1 2026 stood at $35.8 million, up from -$2.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $35.8 million in Q1 2026, with the low at -$17.8 million in Q3 2022.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of -$2.6 million in 2023.
• Annual changes were most pronounced in 2023 — Net Cash Flow slumped 15785.95% — and 2026, when it jumped 699.2%.
• TriSalus Life Sciences' Net Cash Flow stood at -$2.7 million in 2022, then plunged by 255.5% to -$9.5 million in 2023, then jumped by 70.93% to -$2.8 million in 2024, then gained by 18.64% to -$2.2 million in 2025, then surged by 1690.93% to $35.8 million in 2026.
• The last three Net Cash Flow figures came in at $35.8 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.8 million (Q3 2025), per Business Quant data.